Articles By RheumNow
Better Tests Ahead in Lupus
By RheumNow
The advent of "big data" and "-omics" technologies offers hope that clinicians will soon have better diagnostics for systemic lupus erythematosus, rheumatologists here were told.
Read Article
Update on Vaccines in Autoimmune Patients
By RheumNow
Although both the disease and the treatment for it in rheumatology patients may work at cross-purposes with immunizations, only a very few vaccines are absolutely contraindicated in this population, an infectious disease specialist told rheumatologists here.
Read Article
For RA With COPD, Abatacept is Safe
By RheumNow
Patients with rheumatoid arthritis (RA) who also had chronic obstructive pulmonary disease (COPD) had no increased risk of serious respiratory complications when treated with abatacept (Orencia), a large claims-based analysis found.
Read Article
Resistant Hypertension Common in SLE
By RheumNow
Rates of resistant hypertension were doubled among patients with systemic lupus erythematosus (SLE), significantly increasing their mortality risks, a retrospective single-center study found.
Read Article
Risky Painkillers Commonly Prescribed for Osteoarthritis
By RheumNow
Published guidelines warn that treating osteoarthritis (OA) with opioids and benzodiazepines can boost patients' risk of falling.
Read Article
No Rise in Cancer Risk with Actemra
By RheumNow
In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.
Read Article
First Line IL-1 Inhibition in Systemic JIA
By RheumNow
First-line treatment of systemic juvenile idiopathic arthritis (JIA) with anakinra (Kineret) was highly effective as monotherapy, minimizing the need for glucocorticoids, a single-center prospective study found.
Read Article
Congenital Heart Block: Dangers Ahead
By RheumNow
Children of autoantibody-positive mothers who were born with congenital heart block were at high risk for developing later cardiovascular and autoimmune disorders, as were their siblings, Swedish researchers reported.
Read Article
Dual IL-17 Inhibitor in Psoriasis Succeeds
By RheumNow
Patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of interleukin (IL)-17, data from a randomized trial showed.
Read Article
Medical Meetings: Should I Stay or Should I Go?
By RheumNow
Say a conference in your field was just announced. You think you "should" go, and you know you'll be choosing from many presentation opportunities that feature the latest research — which you want to know about. And you'll get to hang with like minds and talk about things that matter.
Read Article